169 related articles for article (PubMed ID: 19809337)
21. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
[TBL] [Abstract][Full Text] [Related]
22. Quetiapine vs. risperidone in treating psychosis in neurosyphilis: a case report.
Taycan O; Ugur M; Ozmen M
Gen Hosp Psychiatry; 2006; 28(4):359-61. PubMed ID: 16814638
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.
McEvoy JP; Lieberman JA; Perkins DO; Hamer RM; Gu H; Lazarus A; Sweitzer D; Olexy C; Weiden P; Strakowski SD
Am J Psychiatry; 2007 Jul; 164(7):1050-60. PubMed ID: 17606657
[TBL] [Abstract][Full Text] [Related]
24. Quetiapine in adolescent psychosis.
Healy E; Subotsky F; Pipe R
J Am Acad Child Adolesc Psychiatry; 1999 Nov; 38(11):1329. PubMed ID: 10560217
[No Abstract] [Full Text] [Related]
25. Quetiapine in adolescents with non-affective psychotic disorders: an open-label trial.
Holzer L; Preuss U; Baumgartner L; Jaugey L; Urben S; Halfon O; Baumann P
Pharmacopsychiatry; 2011 May; 44(3):87-95. PubMed ID: 21318938
[TBL] [Abstract][Full Text] [Related]
26. A comparison of extrapyramidal symptoms in older outpatients treated with quetiapine or risperidone.
Mintzer JE; Mullen JA; Sweitzer DE
Curr Med Res Opin; 2004 Sep; 20(9):1483-91. PubMed ID: 15383198
[TBL] [Abstract][Full Text] [Related]
27. Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients.
Svestka J; Synek O; Tomanová J; Rodáková I; Cejpková A
Neuro Endocrinol Lett; 2007 Dec; 28(6):881-8. PubMed ID: 18063941
[TBL] [Abstract][Full Text] [Related]
28. Elevated prolactin levels in male youths treated with risperidone and quetiapine.
Stevens JR; Kymissis PI; Baker AJ
J Child Adolesc Psychopharmacol; 2005 Dec; 15(6):893-900. PubMed ID: 16379509
[TBL] [Abstract][Full Text] [Related]
29. Cataractogenic potential of quetiapine versus risperidone in the long-term treatment of patients with schizophrenia or schizoaffective disorder: a randomized, open-label, ophthalmologist-masked, flexible-dose, non-inferiority trial.
Laties AM; Flach AJ; Baldycheva I; Rak I; Earley W; Pathak S
J Psychopharmacol; 2015 Jan; 29(1):69-79. PubMed ID: 25315830
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis.
Sajatovic M; Mullen JA; Sweitzer DE
J Clin Psychiatry; 2002 Dec; 63(12):1156-63. PubMed ID: 12523876
[TBL] [Abstract][Full Text] [Related]
31. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trial.
Gharabawi GM; Greenspan A; Rupnow MF; Kosik-Gonzalez C; Bossie CA; Zhu Y; Kalali AH; Awad AG
BMC Psychiatry; 2006 Oct; 6():45. PubMed ID: 17054789
[TBL] [Abstract][Full Text] [Related]
32. Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis.
Cookson J; Hodgson R; Wildgust HJ
J Psychopharmacol; 2012 May; 26(5 Suppl):42-51. PubMed ID: 22472310
[TBL] [Abstract][Full Text] [Related]
33. Amoxapine as an atypical antipsychotic: a comparative study vs risperidone.
Apiquian R; Fresan A; Ulloa RE; de la Fuente-Sandoval C; Herrera-Estrella M; Vazquez A; Nicolini H; Kapur S
Neuropsychopharmacology; 2005 Dec; 30(12):2236-44. PubMed ID: 15956984
[TBL] [Abstract][Full Text] [Related]
34. The effect of long-term antipsychotic treatment on prolactin.
Staller J
J Child Adolesc Psychopharmacol; 2006 Jun; 16(3):317-26. PubMed ID: 16768639
[TBL] [Abstract][Full Text] [Related]
35. Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate.
Montalvo I; Ortega L; López X; Solé M; Monseny R; Franch J; Vilella E; Labad J
Int Clin Psychopharmacol; 2013 Jan; 28(1):46-9. PubMed ID: 23232756
[TBL] [Abstract][Full Text] [Related]
36. Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis.
Pérez-Iglesias R; Ortiz-Garcia de la Foz V; Martínez García O; Amado JA; Garcia-Unzueta MT; Ayesa-Arriola R; Suarez-Pinilla P; Tabares-Seisdedos R; Crespo-Facorro B
Schizophr Res; 2014 Oct; 159(1):90-4. PubMed ID: 25151200
[TBL] [Abstract][Full Text] [Related]
37. Weight gain--as possible predictor of metabolic syndrome.
Grahovac T; Ružić K; Dadić-Hero E; Sepić-Grahovac D; Sabljić V
Psychiatr Danub; 2011 Mar; 23(1):105-7. PubMed ID: 21448110
[TBL] [Abstract][Full Text] [Related]
38. A study of quetiapine: efficacy and tolerability in psychotic adolescents.
Shaw JA; Lewis JE; Pascal S; Sharma RK; Rodriguez RA; Guillen R; Pupo-Guillen M
J Child Adolesc Psychopharmacol; 2001; 11(4):415-24. PubMed ID: 11838824
[TBL] [Abstract][Full Text] [Related]
39. [Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics].
Fric M; Laux G
Psychiatr Prax; 2003 May; 30 Suppl 2():S97-101. PubMed ID: 14509051
[TBL] [Abstract][Full Text] [Related]
40. Esquire trial: efficacy and adverse effects of quetiapine versus risperidone in first-episode schizophrenia.
Gafoor R; Landau S; Craig TK; Elanjithara T; Power P; McGuire P
J Clin Psychopharmacol; 2010 Oct; 30(5):600-6. PubMed ID: 20814318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
